Auris Medical Holding - Full-year results and near-term trial initiations

Auris recently announced its full-year 2018 financial results and provided an update on its active intranasal betahistine programs. R&D expenditure for the year was down roughly 65% compared to FY17, which reflects the shift to focus on earlier-stage program development. Auris plans to initiate the AM-125 Phase II trial of intranasal betahistine for treating acute vertigo in Q119 following the finalisation of clinical site selection, which it states is nearly complete. Additionally, Auris plans to initiate its AM-201 Phase I trial for olanzapine-induced weight gain in Q119.

Den vollständigen Artikel lesen ...